Drugs, pregnancy, and lactation: ondansetron--troubling data.

of 7

Please download to get full document.

View again

All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
7 pages
0 downs
1. Drugs, pregnancy, and lactation: ondansetron--troubling data. Cases of possible or probable serotonin syndrome have been reported with the use of ondansetron, and…
  • 1. Drugs, pregnancy, and lactation: ondansetron--troubling data. Cases of possible or probable serotonin syndrome have been reported with the use of ondansetron, and because many pregnant women are treated with SSRIs during pregnancy, the potential for serotonin syndrome with an SSRI and ondansetron should be considered. But now that the FDA has approved Di-clegis (doxylamine succinate and pyridoxine hydrochloride) for morning sickness--the doxylamine-pyridoxine combination that has been studied in hundreds of thousands of pregnant women and is a pregnancy category A drug--there is now a safer option for women with NW. Therefore, ondansetron should be used cautiously in pregnant women, and only after drugs with a more established safety record--particularly doxylamine-pyridoxine--have been prescribed. E-mail him at obnews@frontlinemedcom.com. Exposure to ondansetron was not associated with an increased rate of major malformations (at about 3%), or other adverse fetal outcomes, including stillbirth, preterm delivery, and low birth weight, compared with the unexposed pregnancies (N. Dr. 2012;94:22-30). With these recent studies, we are left with contradictory results regarding the risk of birth defects associated with ondansetron exposure in the first trimester, and more studies may be needed.
  • 2. Importantly, potential risks of ondansetron, namely, cardiac arrhythmias and serotonin syndrome--which can be harmful to both the mother and fetus--also should be considered. He also holds the Ivey Chair in Molecular Toxicology at the department of medicine, University of Western Ontario, London. My colleagues and I found no increase in the major malformation rate among the 176 pregnancies of women exposed to ondansetron (a 3.6% rate of major malformations), compared with the rates among women exposed to other antiemetics and those exposed to drugs known not be teratogenic (BJOG 2004;111:940-3). The study used data from the National Birth Defects Prevention Study, looking at the association between NVP and treatments for NVP and cleft palate, and other noncardiac birth detects (Birth Defects Res. But monitoring pregnant women taking ondansetron for NVP for these adverse effects is just as important--particularly because they are prone to electrolyte imbalances, including hypokalemia and hypomagnesemia, specified in the FDA warning. Another recent development is the FDA's announcement in May 2013 that an increased risk for serotonin syndrome in patients taking 5-H[T.sub.3] receptor antagonists, including Zofran, has been identified as a tential safety issue" in the FDA's adverse event reporting database during the first quarter of 2013, and that the agency was investigating this possible association further. Typically, serotonin syndrome occurs with the coadministration of two or more dugs that affect serotonin, usually selective serotonin
  • 3. reuptake inhibitors (SSRIs) or monoamine oxidase (MAO) inhibitors. For some time, the potent antiemetic ondansetron, a 5-H[T.sub.3] receptor antagonist approved for preventing nausea and vomiting related to cancer chemotherapy and surgery, has been used to treat morning sickness, mostly for severe cases of nausea and vomiting in pregnancy (NVP). The warning advised against using ondansetron in patients with congenital long-QT syndrome, and recommended ECG monitoring for certain patients on ondansetron, including those with electrolyte abnormalities. Based on what we hear from women who have been treated with ondansetron during pregnancy and http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d9a71b42-ddfc-49d5-7280-0fc0041dba41 contact Motherisk, most clinicians are not following these recommendations in pregnant women. Scan the code for more at obgynnews.com. Caption: DR. 2013;368:814-23). However, the mean gestational age of exposure was 10 weeks, so half the women who took ondansetron started treatment after that time, past the window of risk for malformations, which may have diluted the risk, if it existed. A Clin. However, this sample size could not rule out less than a threefold increase in malformation rates.
  • 4. More reassuring data became available earlier this year with the publication of a study using data from Danish pregnancy birth, and prescription registries. Therefore, life-threatening serotonin syndrome--characterized by zofran lawsuit louisiana a triad of cognitive or behavioral changes, such as confusion or agitation; autonomic instability; and neuromuscular changes--should be kept in mind as another potential risk for pregnant women taking ondansetron. Based on the available data, one therefore needs to be cautious with ondansetron, considering the potential risks of cardiac malformations and oral clefts with first-trimester exposure, which needs to be studied further, and the maternal risks of serotonin syndrome and cardiac arrhythmias. For about 30 years, there was no drug labeled in the United States for morning sickness, after the unjustified removal of Bendectin (doxylamine-pyridoxine). study that resulted in the approval of Didegis, marketed by Duchesnay USA, and he has served as a consultant to Duchesnay. . J. Koren is professor of pediatrics, pharmacology, pharmacy,
  • 5. medicine, and medical genetics at the University of Toronto. Ondansetron, which blocks the action of serotonin, is marketed as Zofran in the United States and Canada, and is also available in generic formulations. Like most drugs, ondansetron is not labeled for use in pregnancy. But until recently, the limited reproductive safety data available on ondansetron have been somewhat reassuring. In June 2012, the Food and Drug Administration (FDA) issued an updated warning about the possible increased risk of prolongation of the QT interval, which can result in the potentially fatal arrhythmia Torsade de pointes, associated with ondansetron. Med. Teratol. The study compared pregnancy outcomes among almost 2,000 women exposed to ondansetron in pregnancy and women not exposed to the drug between 2004 and 2011. KOREN BY GIDEON KOREN, M.D. Dr. He heads the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation at the Hospital for Sick Children, Toronto, where he is director of the Motherisk Program. Hence, ondansetron has been increasingly used off-label for this indication. Still, this limitation did not deter from the strength of the condusions of the study. But new and troubling evidence suggesting that the drug may be associated with increased risks during pregnancy--both maternal and fetal--has recently become available in the medical literature and elsewhere.
  • 6. In August 2013, at the International Society of Pharmacoepidemiology meeting in Montreal, the results of a different group of Danish researchers using data from the same national registries employed in the study published in February, but with more pregnancies (almost 900,000) over a longer period (1997-2010), detected a twofold increase in congenital heart defects associated with ondansetron during the first trimester of pregnancy. Of the 1,248 women who filled a prescription for ondansetron during the first trimester, 4.7% (58) had a baby with a congenital malformation, compared with 3.5% (31,357) of those who were not exposed to ondansetron; this represented a 30% increased risk (adjusted odds ratio, 1.3). The increased risk was mostly due to the increased prevalence of heart defects. The first published report was a Motherisk study comparing pregnancy outcomes of three groups of women who called a teratogen information service. There was no association with congenital malformations and first-trimester prescriptions for metoclopramide, another drug used to treat hyperemesis gravidarum. In January 2012, a study from the Center for Birth Defects Research and Prevention identified a twofold increased risk for cleft palate associated with ondansetron exposure used for NVP in the first trimester. Mol. Koren was a principal investigator in the
  • 7. U.S. There were over 9,000 pregnant women in the study overall, both cases and controls; 67% reported NVP and 15% used some kind of agent to treat NVP. Engl
  • Related Search
    We Need Your Support
    Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

    Thanks to everyone for your continued support.

    No, Thanks